Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
Public ClinicalTrials.gov record NCT05248594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Hemophilia A (HA) is a rare congenital bleeding disorder characterized by coagulation factor VIII deficiency. In severe HA, defined as plasma FVIII clotting activity \< 1%, bleeding may frequently occur spontaneously, most commonly in joints, leading to painful hemophilic arthropathy and loss of joint function. Patients with moderate or mild hemophilia A, defined as FVIII clotting activity between 1-\<5% and 5-40% respectively, are less likely to have spontaneous bleeding however can have significant bleeding with trauma or surgery. Perioperative management by a hematologist who specializes in hemophilia is needed to ensure hemostasis during surgery. Hemophilia is an X-linked recessive disorder affecting 1 in 5000 to 10,000 males.
Study identification
- NCT ID
- NCT05248594
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Up to 36 Months
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2024
- Primary completion
- Jul 17, 2025
- Completion
- Jul 17, 2025
- Last update posted
- Sep 7, 2025
2024 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 4
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Connecticut Children's Hemophilia Treatment Center - Connecticut Children's Medical Center | Hartford | Connecticut | 06106 | — |
| Yale Hemophilia Treatment Center | New Haven | Connecticut | 06510 | — |
| Dartmouth Hitchcock Hemophilia Center - Mary Hitchcock Memorial Hospital | Lebanon | New Hampshire | 03766 | — |
| Newark Beth Israel | Newark | New Jersey | 07112 | — |
| Western NY Blood Care - Research Foundation for SUNY | Buffalo | New York | 14202 | — |
| Comprehensive Center for Hemophilia and Coagulation Disorders (Cornell) | New York | New York | 10065 | — |
| Mary M Gooley Hemophilia Center, Inc. | Rochester | New York | 14621 | — |
| Northwell Health Hemostasis and Thrombosis Center | Staten Island | New York | 11030 | — |
| SUNY Upstate Hemophilia Treatment Center - HTC 058 | Syracuse | New York | 13210 | — |
| Children's Hospital at Montefiore | The Bronx | New York | 10467 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05248594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2025 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05248594 live on ClinicalTrials.gov.